Sign in
Taking people in United StatesNo phase

Follows women with sickle cell disease and their babies after hydroxyurea exposure

Records the effects of hydroxyurea on women with sickle cell disease and their babies.

Key facts

Who runs it
Children's Hospital Medical Center, Cincinnati
Where
Cincinnati, United StatesSee the site
Trial code
Registry title
Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation
Status
Recruiting
People taking part
200 people, planned
Started
22 Dec 2019
Expected to end
31 Dec 2030
Type of study
Observational, 2 groups
Treatments tested
  • Chart Review
  • Survey
Record updated
18 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women with sickle cell disease who were pregnant and took hydroxyurea during pregnancy or breastfeeding, and for their babies. It uses past medical records.

Sex
All sexes are listed in the record; the trial looks at women with sickle cell disease and their babies.
Disease stage
Sickle cell disease
Earlier treatment
Hydroxyurea exposure during pregnancy and/or while breastfeeding.

Main reasons for not taking part

  • Medical records are not available
  • No information about hydroxyurea exposure

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Medical records or data available from previous clinical care prior to June 20, 2019 of pregnant females with SCD, including women who miscarried, had a still birth, or completed labor at any gestational stage, with any hydroxyurea exposure during either pregnancy and/or while breastfeeding
  • Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women

Who cannot take part

  • Unavailable medical records or lack of information about hydroxyurea exposure

Where in United States

  • Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Teresa LathamTaking people

About the trial

What the trial wants to find out

The purpose of this research study is to document and understand the effects of hydroxyurea exposure for women with SCD and their babies, during both gestation and lactation.

The 2 groups in the trial

  • Retrospective Chart Review

    Medical record chart review of women seen previously for clinical care prior to June 20, 2019 at participating institutions with SCD and hydroxyurea exposure during gestation or lactation will be identified by healthcare providers.

    Treatment: Chart Review

  • Participant Survey and Retrospective Chart Review

    Participants providing their medical records without the assistance of a health care provider will be asked to complete a questionnaire through REDCap and will have the option to upload their deidentified medical records if they are available.

    Treatment: Chart Review and Survey

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation
Plain-language title
Follows women with sickle cell disease and their babies after hydroxyurea exposureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
18 June 2026